WuXi AppTec's (HKG:2359, SHA:603259) subsidiaries WuXi ATU (Ireland) Holding and WuXi ATU (Hong Kong) agreed to sell all the shares held by them in the WuXi Advanced Therapies and Oxford Genetics to Altaris for cash consideration, a Tuesday Hong Kong bourse filing said.
Altaris is a medical healthcare industry-focused equity investment fund based in the U.S.A., while WuXi Advanced Therapies and Oxford Genetics are U.S. and United Kingdom operating entities of the WuXi ATU business.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。